医学
抗核抗体
内科学
肺癌
恶化
入射(几何)
不利影响
抗体
胃肠病学
相伴的
肿瘤科
免疫学
自身抗体
光学
物理
作者
Yasuto Yoneshima,Kentaro Tanaka,Yoshimasa Shiraishi,Kojiro Hata,Hiroyuki Watanabe,Taishi Harada,Isamu Okamoto,Eiji Iwama,Hiroyuki Inoue,Satohiro Masuda,Yoichi Nakanishi,Isamu Okamoto
出处
期刊:Lung Cancer
[Elsevier]
日期:2019-04-01
卷期号:130: 5-9
被引量:47
标识
DOI:10.1016/j.lungcan.2019.01.014
摘要
To examine the possible effects of antinuclear antibodies (ANA) on the safety and efficacy of programmed cell death-1 (PD-1) inhibitors in patients with advanced non-small cell lung cancer (NSCLC).Clinical data including ANA status were reviewed retrospectively for patients with advanced NSCLC who received monotherapy with a PD-1 inhibitor.Of the 83 patients analyzed, 18 (21.7%) were positive for ANA. The incidence of immune-related adverse events (irAEs) did not differ significantly between patients with ANA (6/18, 33.3%) and those negative for ANA (21/65, 32.3%), although it tended to increase as the ANA titer increased. Progression-free survival (2.9 versus 3.8 months, p = 0.03) and overall survival (11.6 versus 15.8 months, p = 0.03) were significantly shorter in patients positive for ANA than in those without ANA.PD-1 inhibitors can be administered safely in advanced NSCLC patients positive for ANA without obvious exacerbation of autoimmune disease, although patients with a high titer of such antibodies may warrant close monitoring. However, the presence of ANA might be associated with a poor outcome of such treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI